Anthony Harrelson of Virginia is the founder and CEO of a company that is focused on developing and commercializing immunotherapies for the treatment of infectious diseases, including Ebola and HIV. He is encouraged that the tide appears to be turning in the global struggle against the Ebola virus, but concedes that there is still a long way to go.
As of late January, 2015, he says that there were fewer than one hundred new cases of Ebola in the West African countries that have been hardest-hit by the disease. That is the lowest number of new weekly infections in more than six months. The World Health Organization says that the response to Ebola is entering what it termed a second phase, with efforts shifting to ending the outbreak completely. Up until that time the effort had been focused merely on slowing it down.
Anthony Harrelson of Virginia says that there is a tremendous need to provide an active immunotherapy that can overcome the resistance mechanisms of viral infections, and train the human immune system to respond to infected cells, wherever they might be in the body. This is the goal that he has set for his company, White Oak Industries, Inc. "No one else has yet developed customized immunotherapy using the virus from the individual host. We have."
He says that by using the company's proprietary, patent-pending perfusion hyperthermia system a patient's blood is pumped in to a heating a device. The blood is then heated, filtered, and cooled, after which it is returned to the patient's body in a continuous cycle.
"Cells infected with any deadly viral load including HIV, which causes AIDS, would die during the heating more readily than healthy cells," says Anthony Harrelson of Virginia. "This would allow the healthy cells that were injected into the patient, pre-hyperthermic treatment, to repopulate, with the potential to defend against infection. This would include killing off any deadly virus, such as HIV, that was not killed from the heating of the blood during perfusion. This is the ideal treatment for patients who have failed or are failing, failing pharmaceutical HIV drug treatments, or any deadly viral infection for that matter."

For more information visit at: http://www.authorstream.com/anthonyharrelson/